LitCovid-ArguminSci  

PubMed:32171193 JSONTXT 38 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-120 DRI_Background denotes Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.
T2 121-263 DRI_Challenge denotes COVID-19 (coronavirus disease-19) involves humans as well as animals and may cause serious damage to the respiratory tract including the lung.
T3 264-408 DRI_Challenge denotes This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease.
T4 409-617 DRI_Background denotes When COVID-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1b and IL-6.
T5 618-872 DRI_Challenge denotes The binding of COVID-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1b which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1b which is a mediator of lung inflammation, fever and fibrosis.
T6 873-1037 DRI_Background denotes Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections.
T7 1038-1197 DRI_Challenge denotes Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Ra receptor.
T8 1198-1318 DRI_Background denotes IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase.
T9 1319-1500 DRI_Outcome denotes This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1β, IL-6, TNF and CCL2.
T10 1501-1630 DRI_Background denotes The suppression of IL-1b by IL-37 in inflammatory state induced by COVID-19 can have a new therapeutic effect previously unknown.
T11 1631-1784 DRI_Background denotes Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages.
T12 1785-1887 DRI_Background denotes IL-38 is also a suppressor cytokine which inhibits IL-1b and other pro-inflammatory IL-family members.
T13 1888-2047 DRI_Challenge denotes IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by COVID-19, providing a new relevant strategy.